AstraZeneca PLC's coronavirus vaccine contributed $0.01 to earnings per share in the third quarter, though the company lost $0.03 per share from its development since the start of the year. "AstraZeneca Swung to 3Q Loss Despite Higher Revenue; Continues to Lose Money From Covid-19 Vaccine," at 0741 GMT, incorrectly said that development of the vaccine shaved $0.01 off earnings in the third quarter.

(END) Dow Jones Newswires

November 12, 2021 04:52 ET (09:52 GMT)

Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2022 até Mai 2022

Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mai 2021 até Mai 2022